+1 #(S1 (S (NP (NP (JJ Phosphoinositide) (NN hydrolysis)) (, ,) (VP (VBG resulting) (PP (IN in) (NP (NP (NP (NP (NN _PROT1_) (NN _PROT1_)) (PRN (-LRB- -LRB-) (NP (NN IP3)) (-RRB- -RRB-))) (CC and) (NP (NP (NN diacylglycerol)) (PRN (-LRB- -LRB-) (NP (NN DG)) (-RRB- -RRB-)))) (NN formation)))) (, ,)) (VP (VBZ has) (VP (VBN been) (VP (VBN implicated) (PP (IN in) (NP (NP (JJ _PROT2_) (JJ pulsatile) (NN secretion)) (PP (IN of) (NP (NP (NN prostaglandin) (NN F2) (NN alpha)) (PRN (-LRB- -LRB-) (NP (NN PGF2) (NN alpha)) (-RRB- -RRB-)))) (PP (IN from) (NP (NP (NN uterine) (NN endometrium)) (PP (IN of) (NP (NP (NN sheep)) (CC and) (NP (JJ other) (NNS mammals)))))))))))))
-1 #(S1 (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NP (NN prostaglandin) (NN F2) (NN alpha)) (PRN (-LRB- -LRB-) (NP (NN PGF2) (NN alpha)) (-RRB- -RRB-)))) (PP (IN on) (NP (NP (NP (JJ intracellular) (NN Ca2+) (NN concentration)) (PRN (-LRB- -LRB-) (NP (NN [Ca2+) (-RRB- -RSB-) (CD i)) (-RRB- -RRB-))) (CC and) (NP (NP (NP (NP (NN _PROT1_) (NN _PROT1_)) (PRN (-LRB- -LRB-) (NP (NN IP)) (-RRB- -RRB-))) (NN generation)) (PP (IN in) (NP (JJ human) (NN myometrial) (NNS cells))))))) (VP (VBD were) (VP (VP (VBN evaluated)) (CC and) (VP (VBN compared) (PP (TO to) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NN _PROT2_))))))))))
+1 #(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NP (DT the) (NNS potencies)) (PP (IN of) (NP (NN _PROT1_))) (S (VP (TO to) (VP (VB raise) (NP (NP (NN _PROT2_)) (CC and) (NP (NN [Ca2+) (-RRB- -RSB-) (CD i))))))) (VP (VP (VBD were) (ADJP (ADJP (JJ similar)) (CC and) (ADJP (JJ independent) (PP (IN of) (NP (JJ extracellular) (NN Ca2+)))))) (, ,) (CC and) (VP (MD could) (VP (VB be) (VP (VBN suppressed) (PP (PP (IN by) (NP (NP (NN pertussis) (NN toxin)) (CC and) (NP (NN phorbol) (NN ester)))) (, ,) (CC but) (PP (RB not) (IN by) (NP (NN verapamil))))))))))
+1 #(S1 (S (NP (NP (DT The) (NN action)) (PP (IN of) (NP (NN PGF2) (NN alpha)))) (VP (VBZ depends) (PP (IN on) (NP (JJ extracellular) (NN Ca2+))) (, ,) (SBAR (IN whereas) (S (NP (NN _PROT1_)) (VP (VBZ activates) (NP (NP (DT the) (JJ G-protein-dependent) (NN _PROT2_) (JJ signal-transducing) (NN pathway)) (, ,) (VP (VBN complemented) (PP (IN by) (NP (NP (DT the) (NN influx)) (PP (IN of) (NP (JJ extracellular) (NN Ca2+)))))))))))))
-1 #(S1 (S (NP (DT This)) (VP (VBZ indicates) (SBAR (IN that) (S (NP (NP (DT the) (NN calcium) (NN response)) (PP (TO to) (NP (NN _PROT1_) (NN application)))) (VP (VBD was) (ADVP (RB principally)) (VP (VBN associated) (PP (IN with) (NP (NP (NN activation)) (PP (IN of) (NP (DT the) (JJ _PROT2_) (NN calcium) (NNS stores))))))))))))
-1 #(S1 (S (NP (NP (JJ Homogeneous) (NN liposome) (NN immunoassay)) (PP (IN for) (NP (NN _PROT1_))) (VP (VBG using) (NP (NP (NN _PROT2_) (NN _PROT2_)) (PP (IN from) (NP (NN Clostridium) (NNS perfringens))))))))
-1 #(S1 (S (NP (NN _PROT1_)) (VP (VBD was) (VP (VBN conjugated) (PP (TO to) (NP (NN _PROT2_) (NN _PROT2_))) (PP (IN by) (NP (NP (NP (DT a) (JJ three-step) (NN procedure)) (PP (IN with) (NP (NP (JJ hetero-bifunctional) (NN crosslinking) (NNS reagents)) (, ,) (ADJP (NN succinimidyl) (CD 4-) (-LRB- -LRB-) (NN N-maleimidomethyl) (-RRB- -RRB-) (JJ cyclohexane-1-carboxylate))))) (CC and) (NP (NP (ADJP (CD 3-) (-LRB- -LRB-) (NN 2-pyridyldithio) (-RRB- -RRB-) (JJ propionic)) (NN acid)) (NN N-hydroxysuccinimide) (NN ester))))))))
-1 #(S1 (S (NP (NP (CC Both) (NP (NN p-nitrophenylphosphatidylcholine) (JJ hydrolytic) (NN activity)) (CC and) (NP (NN liposome) (JJ lytic) (NN activity))) (PP (IN of) (NP (JJ _PROT1_AND_PROT2_) (NN _PROT2_) (NN conjugate)))) (VP (VBD were) (VP (VBN inhibited) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NN _PROT_) (NN antiserum)))))))))
-1 #(S1 (S (NP (NP (CC Both) (NP (NN p-nitrophenylphosphatidylcholine) (JJ hydrolytic) (NN activity)) (CC and) (NP (NN liposome) (JJ lytic) (NN activity))) (PP (IN of) (NP (JJ _PROT1_) (NN _PROT_) (NN conjugate)))) (VP (VBD were) (VP (VBN inhibited) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NN _PROT2_) (NN antiserum)))))))))
-1 #(S1 (S (NP (NP (CC Both) (NP (NN p-nitrophenylphosphatidylcholine) (JJ hydrolytic) (NN activity)) (CC and) (NP (NN liposome) (JJ lytic) (NN activity))) (PP (IN of) (NP (JJ _PROT1_) (NN _PROT1_) (NN conjugate)))) (VP (VBD were) (VP (VBN inhibited) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NN _PROT2_) (NN antiserum)))))))))
-1 #(S1 (S (NP (NN _PROT1_) (NN secretion)) (VP (VBZ is) (VP (VBN regulated) (PP (PP (IN by) (NP (NP (NNS changes)) (PP (IN in) (NP (NN blood) (NN glucose))))) (, ,) (CONJP (RB as) (RB well) (IN as)) (PP (IN by) (NP (NP (NP (NP (NNS peptides)) (PP (IN from) (NP (DT the) (JJ gastrointestinal) (NN tract)))) (CC and) (NP (NNS neurotransmitters))) (SBAR (WHNP (WDT that)) (S (VP (VBP activate) (NP (NP (NP (DT the) (JJ pancreatic) (NN islet) (JJ adenylyl) (NN cyclase)) (PRN (-LRB- -LRB-) (NP (FW e.g.) (, ,) (JJ glucagon-like) (NN peptide-1)) (-RRB- -RRB-))) (CC and) (NP (NP (NP (NN _PROT2_) (NN _PROT2_)) (PRN (-LRB- -LRB-) (NP (NN PLC)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NN acetylcholine))) (-RRB- -RRB-))) (NP (NN signaling) (NNS pathways))) (S (VP (TO to) (ADVP (RB further)) (VP (VB potentiate) (NP (JJ glucose-induced) (NN _PROT_) (NN secretion)))))))))))))))
-1 #(S1 (S (NP (NN _PROT1_) (NN secretion)) (VP (VBZ is) (VP (VBN regulated) (PP (PP (IN by) (NP (NP (NNS changes)) (PP (IN in) (NP (NN blood) (NN glucose))))) (, ,) (CONJP (RB as) (RB well) (IN as)) (PP (IN by) (NP (NP (NP (NP (NNS peptides)) (PP (IN from) (NP (DT the) (JJ gastrointestinal) (NN tract)))) (CC and) (NP (NNS neurotransmitters))) (SBAR (WHNP (WDT that)) (S (VP (VBP activate) (NP (NP (NP (DT the) (JJ pancreatic) (NN islet) (JJ adenylyl) (NN cyclase)) (PRN (-LRB- -LRB-) (NP (FW e.g.) (, ,) (JJ glucagon-like) (NN peptide-1)) (-RRB- -RRB-))) (CC and) (NP (NP (NP (NN _PROT_) (NN _PROT_)) (PRN (-LRB- -LRB-) (NP (NN PLC)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NN acetylcholine))) (-RRB- -RRB-))) (NP (NN signaling) (NNS pathways))) (S (VP (TO to) (ADVP (RB further)) (VP (VB potentiate) (NP (JJ glucose-induced) (NN _PROT2_) (NN secretion)))))))))))))))
+1 #(S1 (S (NP (NN _PROT_) (NN secretion)) (VP (VBZ is) (VP (VBN regulated) (PP (PP (IN by) (NP (NP (NNS changes)) (PP (IN in) (NP (NN blood) (NN glucose))))) (, ,) (CONJP (RB as) (RB well) (IN as)) (PP (IN by) (NP (NP (NP (NP (NNS peptides)) (PP (IN from) (NP (DT the) (JJ gastrointestinal) (NN tract)))) (CC and) (NP (NNS neurotransmitters))) (SBAR (WHNP (WDT that)) (S (VP (VBP activate) (NP (NP (NP (DT the) (JJ pancreatic) (NN islet) (JJ adenylyl) (NN cyclase)) (PRN (-LRB- -LRB-) (NP (FW e.g.) (, ,) (JJ glucagon-like) (NN peptide-1)) (-RRB- -RRB-))) (CC and) (NP (NP (NP (NN _PROT1_) (NN _PROT1_)) (PRN (-LRB- -LRB-) (NP (NN PLC)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NN acetylcholine))) (-RRB- -RRB-))) (NP (NN signaling) (NNS pathways))) (S (VP (TO to) (ADVP (RB further)) (VP (VB potentiate) (NP (JJ glucose-induced) (NN _PROT2_) (NN secretion)))))))))))))))
+1 #(S1 (S (ADVP (RB However)) (, ,) (NP (NN leptin)) (VP (VBD did) (VP (VB constrain) (NP (NP (DT the) (VBN enhanced) (JJ _PROT1_) (NN _PROT2_) (NN secretion)) (ADJP (JJ characteristic) (PP (IN of) (NP (NP (NNS islets)) (PP (IN from) (NP (NN ob/ob) (NNS mice))))))) (, ,) (PP (IN without) (S (VP (VBG influencing) (NP (NP (NN release)) (PP (IN from) (NP (NP (NNS islets)) (PP (IN of) (NP (JJ lean) (NNS mice)))))))))))))
+1 #(S1 (S (NP (NP (DT A) (JJ specific) (NN enhancement)) (PP (IN in) (NP (JJ _PROT1_) (NN _PROT2_) (NN secretion)))) (VP (VBZ is) (NP (NP (DT the) (JJS earliest) (VBN reported) (JJ developmental) (NN alteration)) (PP (IN in) (NP (NP (NN _PROT_) (NN secretion)) (PP (IN from) (NP (NP (NNS islets)) (PP (IN of) (NP (NN ob/ob) (NNS mice))))))))) (, ,) (CONJP (CC and) (RB thus)) (NP (NP (DT a) (JJ logical) (NN target)) (PP (IN for) (NP (NN leptin) (NN action))))))
-1 #(S1 (S (NP (NP (DT A) (JJ specific) (NN enhancement)) (PP (IN in) (NP (JJ _PROT1_) (NN _PROT_) (NN secretion)))) (VP (VBZ is) (NP (NP (DT the) (JJS earliest) (VBN reported) (JJ developmental) (NN alteration)) (PP (IN in) (NP (NP (NN _PROT2_) (NN secretion)) (PP (IN from) (NP (NP (NNS islets)) (PP (IN of) (NP (NN ob/ob) (NNS mice))))))))) (, ,) (CONJP (CC and) (RB thus)) (NP (NP (DT a) (JJ logical) (NN target)) (PP (IN for) (NP (NN leptin) (NN action))))))
-1 #(S1 (S (NP (NP (DT A) (JJ specific) (NN enhancement)) (PP (IN in) (NP (JJ _PROT_) (NN _PROT1_) (NN secretion)))) (VP (VBZ is) (NP (NP (DT the) (JJS earliest) (VBN reported) (JJ developmental) (NN alteration)) (PP (IN in) (NP (NP (NN _PROT2_) (NN secretion)) (PP (IN from) (NP (NP (NNS islets)) (PP (IN of) (NP (NN ob/ob) (NNS mice))))))))) (, ,) (CONJP (CC and) (RB thus)) (NP (NP (DT a) (JJ logical) (NN target)) (PP (IN for) (NP (NN leptin) (NN action))))))
+1 #(S1 (S (S (NP (NP (DT This) (NN action)) (PP (IN of) (NP (NN leptin))) (PP (IN on) (NP (JJ _PROT1_) (NN _PROT2_) (NN secretion)))) (VP (VBD was) (ADJP (ADJP (JJ dose-dependent)) (, ,) (ADJP (JJ rapid-onset))) (PRN (-LRB- -LRB-) (PP (FW i.e.)) (, ,) (PP (IN within) (NP (CD 3) (NN min))) (-RRB- -RRB-)))) (, ,) (CC and) (ADVP (JJ reversible))))
-1 #(S1 (S (NP (NN Leptin)) (VP (VBD was) (ADJP (RB equally) (JJ effective) (PP (IN in) (S (VP (VBG constraining) (NP (NP (DT the) (VBN enhanced) (NN _PROT1_) (NN release)) (PP (IN from) (NP (NP (NNS islets)) (PP (IN of) (NP (NN ob/ob) (NNS mice))) (VP (VBN caused) (PP (IN by) (NP (NP (NP (NN protein) (NN kinase) (NN C)) (PRN (-LRB- -LRB-) (NP (NN PKC)) (-RRB- -RRB-))) (NN activation))))))))))) (, ,) (NP (NP (DT a) (JJ downstream) (NN mediator)) (PP (IN of) (NP (DT the) (NN _PROT2_) (NN signal) (NN pathway)))))))
-1 #(S1 (S (NP (NP (CD One) (NN function)) (PP (IN of) (NP (NN leptin))) (PP (IN in) (NP (NP (NN control)) (PP (IN of) (NP (NN body) (NN composition)))))) (VP (VBZ is) (S (ADVP (RB thus)) (VP (TO to) (VP (VB target) (NP (NP (DT a) (JJ PKC-regulated) (NN component)) (PP (IN of) (NP (NP (DT the) (JJ _PROT1_) (NN signaling) (NN system)) (PP (IN within) (NP (NNS islets)))))) (S (VP (TO to) (VP (VB prevent) (NP (NP (NN hypersecretion)) (PP (IN of) (NP (NN _PROT2_)))))))))))))
+1 #(S1 (S (ADVP (RB However)) (, ,) (PP (IN in) (NP (NN brown) (NN fat))) (, ,) (NP (PRP we)) (VP (VBD observed) (NP (NP (DT a) (JJ 2-3-fold) (NN increase)) (PP (IN in) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NN _PROT1_))) (PP (IN in) (NP (NP (NN response)) (PP (TO to) (NP (JJ dietary) (JJ fat) (NN challenge))))))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (VB be) (ADJP (JJ related) (PP (TO to) (NP (NP (JJ diet-induced) (NNS elevations)) (PP (IN in) (NP (NN plasma) (NN _PROT2_) (NNS levels))))))))))))))
-1 #(S1 (S (NP (NN _PROT1_)) (VP (VBZ evokes) (NP (NP (DT the) (NN release)) (PP (IN of) (NP (NN Ca2+))) (PP (IN from) (NP (JJ _PROT2_) (JJ intracellular) (NNS stores)))))))
+1 #(S1 (S (NP (NP (DT A) (NN barley) (NN gene)) (VP (VBG encoding) (NP (NP (DT a) (JJ novel) (JJ DNA-binding) (NN protein)) (PRN (-LRB- -LRB-) (NP (NN HRT)) (-RRB- -RRB-))))) (VP (VBD was) (VP (VBN identified) (PP (IN by) (NP (NP (NN southwestern) (NN screening)) (PP (IN with) (NP (NP (NNS baits)) (VP (VBG containing) (NP (DT a) (NN _PROT1_) (NN phytohormone) (NN response) (NN element)) (PP (IN from) (NP (DT an) (NN _PROT2_) (NN promoter))))))))))))
+1 #(S1 (S (NP (NP (NP (JJ Oxytocin-stimulated) (NN _PROT1_) (NN release)) (PP (IN in) (NP (DT a) (JJ clonal) (NN beta-cell) (NN line) (CD RINm5F)))) (: :) (NP (NP (NN involvement)) (PP (IN of) (NP (ADJP (ADJP (NN _PROT2_) (JJ _PROT2_)) (CC and) (ADJP (JJ -independent))) (NNS pathways)))) (. .))))
+1 #(S1 (S (NP (NP (NN CONCLUSION)) (: :) (S (NP (NN Oxy)) (VP (VBZ increases) (NP (NN _PROT1_) (NN release)) (PP (IN through) (NP (CC both) (NP (NN _PROT2_)) (CC and) (NP (NN non-PLC)) (NP (VBN mediated) (NN signal) (NN transduction) (NNS mechanisms)))))) (. .))))
+1 #(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NN U-73122)) (VP (VBD diminished) (NP (NP (DT the) (JJ _PROT1_) (NN increase)) (PP (IN in) (NP (NP (JJ intracellular) (NN concentration)) (PP (IN of) (NP (NN _PROT2_) (CD _PROT2_)))))) (, _PROT2_) (S (NP (NP (CD _PROT2_)) (, _PROT2_) (NP (NP (NN _PROT2_)) (PRN (-LRB- -LRB-) (NP (NN IP3)) (-RRB- -RRB-))))))))
+1 #(S1 (S (S (NP (NP (NN U-73122)) (PP (IN at) (NP (CD 8) (NN mumol.L-1)))) (ADVP (RB totally)) (VP (VBD abolished) (NP (NP (DT the) (JJ _PROT1_) (NNS increases)) (PP (IN in) (NP (NP (NN [Ca2+) (-RRB- -RSB-) (CD i)) (CC and) (NP (NN _PROT2_))))))) (: ;) (RB however) (S (NP (PRP it)) (VP (VBD reduced) (NP (NP (DT the) (JJ _PROT_) (NN increase)) (PP (IN in) (NP (NN insulin) (NN release)))) (PP (ADVP (RB only)) (IN by) (NP (NP (NP (CD 36) (NN %)) (CC and) (NP (CD 63) (NN %))) (PP (IN in) (NP (DT the) (NN monolayer) (CC and) (JJ suspended) (NN cell) (NNS preparations))))) (, ,) (ADVP (RB respectively))))))
-1 #(S1 (S (S (NP (NP (NN U-73122)) (PP (IN at) (NP (CD 8) (NN mumol.L-1)))) (ADVP (RB totally)) (VP (VBD abolished) (NP (NP (DT the) (JJ _PROT1_) (NNS increases)) (PP (IN in) (NP (NP (NN [Ca2+) (-RRB- -RSB-) (CD i)) (CC and) (NP (NN _PROT_))))))) (: ;) (RB however) (S (NP (PRP it)) (VP (VBD reduced) (NP (NP (DT the) (JJ _PROT2_) (NN increase)) (PP (IN in) (NP (NN insulin) (NN release)))) (PP (ADVP (RB only)) (IN by) (NP (NP (NP (CD 36) (NN %)) (CC and) (NP (CD 63) (NN %))) (PP (IN in) (NP (DT the) (NN monolayer) (CC and) (JJ suspended) (NN cell) (NNS preparations))))) (, ,) (ADVP (RB respectively))))))
-1 #(S1 (S (S (NP (NP (NN U-73122)) (PP (IN at) (NP (CD 8) (NN mumol.L-1)))) (ADVP (RB totally)) (VP (VBD abolished) (NP (NP (DT the) (JJ _PROT_) (NNS increases)) (PP (IN in) (NP (NP (NN [Ca2+) (-RRB- -RSB-) (CD i)) (CC and) (NP (NN _PROT1_))))))) (: ;) (RB however) (S (NP (PRP it)) (VP (VBD reduced) (NP (NP (DT the) (JJ _PROT2_) (NN increase)) (PP (IN in) (NP (NN insulin) (NN release)))) (PP (ADVP (RB only)) (IN by) (NP (NP (NP (CD 36) (NN %)) (CC and) (NP (CD 63) (NN %))) (PP (IN in) (NP (DT the) (NN monolayer) (CC and) (JJ suspended) (NN cell) (NNS preparations))))) (, ,) (ADVP (RB respectively))))))
+1 #(S1 (S (NP (NP (NP (JJ _PROT1_) (NN _PROT2_) (NN release)) (PP (IN in) (NP (DT a) (JJ clonal) (NN beta-cell) (NN line) (CD RINm5F)))) (: :) (NP (NP (NN involvement)) (PP (IN of) (NP (ADJP (ADJP (NN phospholipase) (JJ C-dependent)) (CC and) (ADJP (JJ -independent))) (NNS pathways)))))))
+1 #(S1 (S (NP (NP (NN AIM)) (: :) (S (VP (TO To) (VP (VB study) (NP (NP (DT the) (NNS mechanisms)) (VP (VBG underlying) (NP (ADJP (NN _PROT1_) (-LRB- -LRB-) (NN Oxy) (-RRB- -RRB-) (JJ -induced)) (NN _PROT2_) (NN release))))))))))
+1 #(S1 (S (NP (NP (NNS RESULTS)) (: :) (S (NP (NN _PROT1_)) (VP (VBD increased) (NP (NP (NN _PROT2_) (NN release)) (CC and) (NP (NN [Ca2+) (-RRB- -RSB-) (CD i))) (PP (IN in) (NP (DT a) (JJ concentration-dependent) (NN manner))))))))
+1 #(S1 (S (NP (JJ _PROT1_) (NN _PROT2_) (NN release)) (VP (VBD was) (RB not) (VP (VBN altered) (PP (IN by) (NP (NP (NN pretreatment)) (PP (IN with) (NP (NP (NN pertussis) (NN toxin)) (PRN (-LRB- -LRB-) (NP (NN PT)) (-RRB- -RRB-))))))))))
-1 #(S1 (S (S (NP (NP (NN U-73122)) (PP (IN at) (NP (CD 8) (NN mumol.L-1)))) (ADVP (RB totally)) (VP (VBD abolished) (NP (NP (DT the) (JJ _PROT1_) (NNS increases)) (PP (IN in) (NP (NP (NN [Ca2+) (-RRB- -RSB-) (CD i)) (CC and) (NP (NN IP3))))))) (: ;) (RB however) (S (NP (PRP it)) (VP (VBD reduced) (NP (NP (DT the) (JJ _PROT2_) (NN increase)) (PP (IN in) (NP (NN _PROT_) (NN release)))) (PP (ADVP (RB only)) (IN by) (NP (NP (NP (CD 36) (NN %)) (CC and) (NP (CD 63) (NN %))) (PP (IN in) (NP (DT the) (NN monolayer) (CC and) (JJ suspended) (NN cell) (NNS preparations))))) (, ,) (ADVP (RB respectively))))))
-1 #(S1 (S (S (NP (NP (NN U-73122)) (PP (IN at) (NP (CD 8) (NN mumol.L-1)))) (ADVP (RB totally)) (VP (VBD abolished) (NP (NP (DT the) (JJ _PROT1_) (NNS increases)) (PP (IN in) (NP (NP (NN [Ca2+) (-RRB- -RSB-) (CD i)) (CC and) (NP (NN IP3))))))) (: ;) (RB however) (S (NP (PRP it)) (VP (VBD reduced) (NP (NP (DT the) (JJ _PROT_) (NN increase)) (PP (IN in) (NP (NN _PROT2_) (NN release)))) (PP (ADVP (RB only)) (IN by) (NP (NP (NP (CD 36) (NN %)) (CC and) (NP (CD 63) (NN %))) (PP (IN in) (NP (DT the) (NN monolayer) (CC and) (JJ suspended) (NN cell) (NNS preparations))))) (, ,) (ADVP (RB respectively))))))
+1 #(S1 (S (S (NP (NP (NN U-73122)) (PP (IN at) (NP (CD 8) (NN mumol.L-1)))) (ADVP (RB totally)) (VP (VBD abolished) (NP (NP (DT the) (JJ _PROT_) (NNS increases)) (PP (IN in) (NP (NP (NN [Ca2+) (-RRB- -RSB-) (CD i)) (CC and) (NP (NN IP3))))))) (: ;) (RB however) (S (NP (PRP it)) (VP (VBD reduced) (NP (NP (DT the) (JJ _PROT1_) (NN increase)) (PP (IN in) (NP (NN _PROT2_) (NN release)))) (PP (ADVP (RB only)) (IN by) (NP (NP (NP (CD 36) (NN %)) (CC and) (NP (CD 63) (NN %))) (PP (IN in) (NP (DT the) (NN monolayer) (CC and) (JJ suspended) (NN cell) (NNS preparations))))) (, ,) (ADVP (RB respectively))))))
+1 #(S1 (S (NP (NP (NN CONCLUSION)) (: :) (S (NP (NN _PROT1_)) (VP (VBZ increases) (NP (NN _PROT2_) (NN release)) (PP (IN through) (NP (CC both) (NP (NN PLC)) (CC and) (NP (ADJP (NN non-PLC) (JJ mediated)) (NN signal) (NN transduction) (NNS mechanisms)))))))))
-1 #(S1 (S (PP (IN In) (NP (VBN isolated) (NNS adipocytes))) (, ,) (NP (NP (DT the) (NN loss)) (PP (IN of) (NP (RB almost) (NN half)))) (S (NP (NP (DT the) (NN 18S) (NN RNA) (NN content)) (PP (IN over) (NP (DT a) (JJ 24-hour) (NN incubation)))) (VP (VBD was) (VP (VBN prevented) (PP (IN in) (DT the) (NN presence) (IN of) (NP (NP (NP (NN _PROT1_)) (CONJP (CC but) (RB not)) (NP (NN _PROT2_))) (CC or) (NP (NP (JJ epidermal) (NN growth) (NN factor)) (PRN (-LRB- -LRB-) (NP (NN EGF)) (-RRB- -RRB-))))))))))
+1 #(S1 (S (NP (JJ Further) (NN investigation)) (VP (VBD suggested) (SBAR (IN that) (S (NP (NP (NN activation)) (PP (IN of) (NP (NP (NP (NN _PROT1_) (NN _PROT1_) (NN _PROT1_)) (PRN (-LRB- -LRB-) (NP (NN PKC)) (-RRB- -RRB-))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ is) (NP (NP (NN part)) (PP (IN of) (NP (DT the) (JJ _PROT2_) (JJ intracellular) (NN signalling) (NN pathway))))))) (, ,)))) (VP (VBZ is) (ADJP (ADJP (JJ necessary)) (CC and) (ADJP (JJ sufficient)) (PP (IN for) (NP (NP (DT the) (NN generation)) (PP (IN of) (NP (DT the) (JJ synergistic) (NN response)))))) (, ,) (SBAR (IN although) (S (NP (PRP it)) (VP (VBZ is) (RB not) (ADJP (JJ obligatory) (PP (IN for) (NP (JJ _PROT_) (NN ACTH) (NN release)))))))))))))
-1 #(S1 (S (NP (JJ Further) (NN investigation)) (VP (VBD suggested) (SBAR (IN that) (S (NP (NP (NN activation)) (PP (IN of) (NP (NP (NP (NN _PROT1_) (NN _PROT1_) (NN _PROT1_)) (PRN (-LRB- -LRB-) (NP (NN PKC)) (-RRB- -RRB-))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ is) (NP (NP (NN part)) (PP (IN of) (NP (DT the) (JJ _PROT_) (JJ intracellular) (NN signalling) (NN pathway))))))) (, ,)))) (VP (VBZ is) (ADJP (ADJP (JJ necessary)) (CC and) (ADJP (JJ sufficient)) (PP (IN for) (NP (NP (DT the) (NN generation)) (PP (IN of) (NP (DT the) (JJ synergistic) (NN response)))))) (, ,) (SBAR (IN although) (S (NP (PRP it)) (VP (VBZ is) (RB not) (ADJP (JJ obligatory) (PP (IN for) (NP (JJ _PROT2_) (NN ACTH) (NN release)))))))))))))
-1 #(S1 (S (NP (JJ Further) (NN investigation)) (VP (VBD suggested) (SBAR (IN that) (S (NP (NP (NN activation)) (PP (IN of) (NP (NP (NP (NN _PROT_) (NN _PROT_) (NN _PROT_)) (PRN (-LRB- -LRB-) (NP (NN PKC)) (-RRB- -RRB-))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ is) (NP (NP (NN part)) (PP (IN of) (NP (DT the) (JJ _PROT1_) (JJ intracellular) (NN signalling) (NN pathway))))))) (, ,)))) (VP (VBZ is) (ADJP (ADJP (JJ necessary)) (CC and) (ADJP (JJ sufficient)) (PP (IN for) (NP (NP (DT the) (NN generation)) (PP (IN of) (NP (DT the) (JJ synergistic) (NN response)))))) (, ,) (SBAR (IN although) (S (NP (PRP it)) (VP (VBZ is) (RB not) (ADJP (JJ obligatory) (PP (IN for) (NP (JJ _PROT2_) (NN ACTH) (NN release)))))))))))))
+1 #(S1 (S (NP (DT The) (JJ bovine) (JJ ovarian) (NN granulosa) (NN cell) (NN model)) (VP (VBZ is) (NP (NP (DT a) (JJ primary) (NN culture) (NN system)) (SBAR (WHADVP (WRB where)) (S (PP (IN under) (NP (NP (NN stimulation)) (PP (IN by) (NP (NP (NN _PROT1_)) (CC or) (NP (NP (NN IGF-I)) (CC and) (NP (NN LH))))))) (NP (DT the) (JJ endogenous) (NN _PROT2_) (NN gene)) (VP (VBZ is) (ADVP (RB massively)) (VP (VBN upregulated)))))))))
-1 #(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (ADJP (JJ abscisic) (JJ acid-mediated)) (NN inhibition)) (PP (IN of) (NP (JJ _PROT1_) (NNS responses)))) (VP (VBZ seems) (S (VP (TO to) (VP (VB depend) (PP (IN on) (NP (NP (DT the) (NN activation)) (PP (IN of) (NP (DT a) (NN phospholipase) (NN D))) (PP (PP (IN during) (NP (NP (NN induction)) (PP (IN of) (NP (NN _PROT2_))) (PP (IN in) (NP (NN barley) (NN aleurone) (NNS cells))))) (CONJP (RB as) (RB well) (IN as)) (PP (IN on) (NP (NP (DT a) (JJ putative) (NN acetyltransferase)) (VP (VBN involved) (PP (IN in) (NP (NN elongation) (NN growth))))))))))))) (. .)))
+1 #(S1 (S (NP (NP (NNS Effects)) (PP (IN of) (NP (ADJP (RB intravenously) (VBN infused)) (NN _PROT1_))) (PP (PP (IN on) (NP (NN insulin) (NN sensitivity))) (CC and) (PP (IN on) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NN _PROT2_) (NNS _PROT2_))) (PP (IN in) (NP (JJ brown) (NN adipose) (NN tissue)))))))))
+1 #(S1 (S (NP (ADJP (RB Centrally) (VBN administered)) (NN _PROT1_)) (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (S (VP (VP (TO to) (VP (VB increase) (NP (JJ insulin-stimulated) (NN glucose) (NN utilization)))) (CC and) (VP (TO to) (VP (VB favor) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NP (NN _PROT2_) (NNS _PROT2_)) (PRN (-LRB- -LRB-) (NP (NNS UCPs)) (-RRB- -RRB-))))))))))))))
-1 #(S1 (S (S (VP (TO To) (VP (VB study) (SBAR (IN if) (S (NP (NN _PROT1_)) (ADVP (RB also)) (VP (VBZ has) (NP (JJ direct) (ADJP (RB peripherally) (VBN mediated)) (NNS effects)) (PP (IN on) (NP (DT these) (NNS processes))))))))) (, ,) (S (NP (NP (NP (DT this) (NN hormone)) (PRN (-LRB- -LRB-) (NP (CD 1) (NN mg/day)) (-RRB- -RRB-))) (CC or) (NP (PRP$ its) (NN vehicle))) (VP (VBD was) (VP (VBN infused) (PRT (RP i.v.)) (PP (IN for) (NP (NP (CD 4) (NNS days)) (PP (TO to) (NP (JJ lean) (NNS rats)))))))) (CC and) (S (NP (NP (NP (JJ insulin-stimulated) (NN glucose) (NN utilization)) (PP (IN in) (NP (NP (JJ skeletal) (NN muscle)) (CC and) (NP (JJ adipose) (NN tissue))))) (CONJP (RB as) (RB well) (IN as)) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NP (NN _PROT2_) (NN messenger) (NNS RNAs)) (PRN (-LRB- -LRB-) (NP (NNS mRNAs)) (-RRB- -RRB-)))) (PP (IN in) (NP (JJ brown) (NN adipose) (NN tissue))))) (VP (VBD were) (VP (VBN measured))))))
+1 #(S1 (S (S (NP (NN I.v.) (NN _PROT1_) (NN infusion)) (ADVP (RB also)) (VP (VBN favored) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NNS _PROT2_))) (PP (PP (IN in) (NP (JJ brown) (NN adipose) (NN tissue))) (, ,) (CC either) (PP (IN by) (S (VP (VP (VBG increasing) (NP (PRP$ their) (NN expression))) (CC or) (VP (VBG preventing) (S (NP (DT the)) (VP (VBP fall) (VP (VBG occurring) (PP (IN during) (NP (DT the) (JJ pair-feeding) (NN regimen)))))))))))))) (. .)))
-1 #(S1 (S (S (NP (JJ Relative) (NN _PROT1_) (NN expression) (NNS levels)) (VP (VBD were) (NP (NP (QP (CD 100) (, ,) (CD 104) (, ,) (CC and) (CD 33)) (PP (IN for) (NP (NN _PROT2_)))) (, ,) (NP (QP (CD 100) (, ,) (CD 191) (, ,) (CC and) (CD 125)) (PP (IN for) (NP (NN _PROT_)))) (CC and) (NP (QP (CD 100) (, ,) (CD 107) (, ,) (CC and) (CD 29)) (PP (IN for) (NP (NN _PROT_))))) (PP (IN in) (NP (NN ad) (NN libitum) (JJ fed) (NN control) (NNS rats))) (, ,) (PP (PP (IN in) (NP (JJ _PROT_) (NNS rats))) (CC and) (PP (IN in) (NP (JJ pair-fed) (NN control) (NNS rats)))))) (, ,) (RB respectively)))
-1 #(S1 (S (S (NP (JJ Relative) (NN _PROT1_) (NN expression) (NNS levels)) (VP (VBD were) (NP (NP (QP (CD 100) (, ,) (CD 104) (, ,) (CC and) (CD 33)) (PP (IN for) (NP (NN _PROT_)))) (, ,) (NP (QP (CD 100) (, ,) (CD 191) (, ,) (CC and) (CD 125)) (PP (IN for) (NP (NN _PROT2_)))) (CC and) (NP (QP (CD 100) (, ,) (CD 107) (, ,) (CC and) (CD 29)) (PP (IN for) (NP (NN _PROT_))))) (PP (IN in) (NP (NN ad) (NN libitum) (JJ fed) (NN control) (NNS rats))) (, ,) (PP (PP (IN in) (NP (JJ _PROT_) (NNS rats))) (CC and) (PP (IN in) (NP (JJ pair-fed) (NN control) (NNS rats)))))) (, ,) (RB respectively)))
-1 #(S1 (S (S (NP (JJ Relative) (NN _PROT1_) (NN expression) (NNS levels)) (VP (VBD were) (NP (NP (QP (CD 100) (, ,) (CD 104) (, ,) (CC and) (CD 33)) (PP (IN for) (NP (NN _PROT_)))) (, ,) (NP (QP (CD 100) (, ,) (CD 191) (, ,) (CC and) (CD 125)) (PP (IN for) (NP (NN _PROT_)))) (CC and) (NP (QP (CD 100) (, ,) (CD 107) (, ,) (CC and) (CD 29)) (PP (IN for) (NP (NN _PROT2_))))) (PP (IN in) (NP (NN ad) (NN libitum) (JJ fed) (NN control) (NNS rats))) (, ,) (PP (PP (IN in) (NP (JJ _PROT_) (NNS rats))) (CC and) (PP (IN in) (NP (JJ pair-fed) (NN control) (NNS rats)))))) (, ,) (RB respectively)))
-1 #(S1 (S (S (NP (JJ Relative) (NN _PROT1_) (NN expression) (NNS levels)) (VP (VBD were) (NP (NP (QP (CD 100) (, ,) (CD 104) (, ,) (CC and) (CD 33)) (PP (IN for) (NP (NN _PROT_)))) (, ,) (NP (QP (CD 100) (, ,) (CD 191) (, ,) (CC and) (CD 125)) (PP (IN for) (NP (NN _PROT_)))) (CC and) (NP (QP (CD 100) (, ,) (CD 107) (, ,) (CC and) (CD 29)) (PP (IN for) (NP (NN _PROT_))))) (PP (IN in) (NP (NN ad) (NN libitum) (JJ fed) (NN control) (NNS rats))) (, ,) (PP (PP (IN in) (NP (JJ _PROT2_) (NNS rats))) (CC and) (PP (IN in) (NP (JJ pair-fed) (NN control) (NNS rats)))))) (, ,) (RB respectively)))
-1 #(S1 (S (S (NP (JJ Relative) (NN _PROT_) (NN expression) (NNS levels)) (VP (VBD were) (NP (NP (QP (CD 100) (, ,) (CD 104) (, ,) (CC and) (CD 33)) (PP (IN for) (NP (NN _PROT1_)))) (, ,) (NP (QP (CD 100) (, ,) (CD 191) (, ,) (CC and) (CD 125)) (PP (IN for) (NP (NN _PROT2_)))) (CC and) (NP (QP (CD 100) (, ,) (CD 107) (, ,) (CC and) (CD 29)) (PP (IN for) (NP (NN _PROT_))))) (PP (IN in) (NP (NN ad) (NN libitum) (JJ fed) (NN control) (NNS rats))) (, ,) (PP (PP (IN in) (NP (JJ _PROT_) (NNS rats))) (CC and) (PP (IN in) (NP (JJ pair-fed) (NN control) (NNS rats)))))) (, ,) (RB respectively)))
-1 #(S1 (S (S (NP (JJ Relative) (NN _PROT_) (NN expression) (NNS levels)) (VP (VBD were) (NP (NP (QP (CD 100) (, ,) (CD 104) (, ,) (CC and) (CD 33)) (PP (IN for) (NP (NN _PROT1_)))) (, ,) (NP (QP (CD 100) (, ,) (CD 191) (, ,) (CC and) (CD 125)) (PP (IN for) (NP (NN _PROT_)))) (CC and) (NP (QP (CD 100) (, ,) (CD 107) (, ,) (CC and) (CD 29)) (PP (IN for) (NP (NN _PROT2_))))) (PP (IN in) (NP (NN ad) (NN libitum) (JJ fed) (NN control) (NNS rats))) (, ,) (PP (PP (IN in) (NP (JJ _PROT_) (NNS rats))) (CC and) (PP (IN in) (NP (JJ pair-fed) (NN control) (NNS rats)))))) (, ,) (RB respectively)))
-1 #(S1 (S (S (NP (JJ Relative) (NN _PROT_) (NN expression) (NNS levels)) (VP (VBD were) (NP (NP (QP (CD 100) (, ,) (CD 104) (, ,) (CC and) (CD 33)) (PP (IN for) (NP (NN _PROT1_)))) (, ,) (NP (QP (CD 100) (, ,) (CD 191) (, ,) (CC and) (CD 125)) (PP (IN for) (NP (NN _PROT_)))) (CC and) (NP (QP (CD 100) (, ,) (CD 107) (, ,) (CC and) (CD 29)) (PP (IN for) (NP (NN _PROT_))))) (PP (IN in) (NP (NN ad) (NN libitum) (JJ fed) (NN control) (NNS rats))) (, ,) (PP (PP (IN in) (NP (JJ _PROT2_) (NNS rats))) (CC and) (PP (IN in) (NP (JJ pair-fed) (NN control) (NNS rats)))))) (, ,) (RB respectively)))
-1 #(S1 (S (S (NP (JJ Relative) (NN _PROT_) (NN expression) (NNS levels)) (VP (VBD were) (NP (NP (QP (CD 100) (, ,) (CD 104) (, ,) (CC and) (CD 33)) (PP (IN for) (NP (NN _PROT_)))) (, ,) (NP (QP (CD 100) (, ,) (CD 191) (, ,) (CC and) (CD 125)) (PP (IN for) (NP (NN _PROT1_)))) (CC and) (NP (QP (CD 100) (, ,) (CD 107) (, ,) (CC and) (CD 29)) (PP (IN for) (NP (NN _PROT2_))))) (PP (IN in) (NP (NN ad) (NN libitum) (JJ fed) (NN control) (NNS rats))) (, ,) (PP (PP (IN in) (NP (JJ _PROT_) (NNS rats))) (CC and) (PP (IN in) (NP (JJ pair-fed) (NN control) (NNS rats)))))) (, ,) (RB respectively)))
-1 #(S1 (S (S (NP (JJ Relative) (NN _PROT_) (NN expression) (NNS levels)) (VP (VBD were) (NP (NP (QP (CD 100) (, ,) (CD 104) (, ,) (CC and) (CD 33)) (PP (IN for) (NP (NN _PROT_)))) (, ,) (NP (QP (CD 100) (, ,) (CD 191) (, ,) (CC and) (CD 125)) (PP (IN for) (NP (NN _PROT1_)))) (CC and) (NP (QP (CD 100) (, ,) (CD 107) (, ,) (CC and) (CD 29)) (PP (IN for) (NP (NN _PROT_))))) (PP (IN in) (NP (NN ad) (NN libitum) (JJ fed) (NN control) (NNS rats))) (, ,) (PP (PP (IN in) (NP (JJ _PROT2_) (NNS rats))) (CC and) (PP (IN in) (NP (JJ pair-fed) (NN control) (NNS rats)))))) (, ,) (RB respectively)))
-1 #(S1 (S (S (NP (JJ Relative) (NN _PROT_) (NN expression) (NNS levels)) (VP (VBD were) (NP (NP (QP (CD 100) (, ,) (CD 104) (, ,) (CC and) (CD 33)) (PP (IN for) (NP (NN _PROT_)))) (, ,) (NP (QP (CD 100) (, ,) (CD 191) (, ,) (CC and) (CD 125)) (PP (IN for) (NP (NN _PROT_)))) (CC and) (NP (QP (CD 100) (, ,) (CD 107) (, ,) (CC and) (CD 29)) (PP (IN for) (NP (NN _PROT1_))))) (PP (IN in) (NP (NN ad) (NN libitum) (JJ fed) (NN control) (NNS rats))) (, ,) (PP (PP (IN in) (NP (JJ _PROT2_) (NNS rats))) (CC and) (PP (IN in) (NP (JJ pair-fed) (NN control) (NNS rats)))))) (, ,) (RB respectively)))
+1 #(S1 (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (DT the) (JJ overall) (NN effect)) (PP (IN of) (NP (NN _PROT1_))) (PP (PP (IN on) (NP (NN glucose) (NN utilization))) (CC and) (PP (IN on) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NNS _PROT2_))))))) (VP (MD may) (VP (VB be) (VP (VBN mediated) (PP (IN through) (NP (JJ central) (NN mechanism)))))))))))
-1 #(S1 (S (NP (NP (DT The) (NN activity)) (PP (IN of) (NP (NN catalase)))) (VP (VBD was) (VP (VBN found) (S (VP (TO to) (VP (VB be) (ADVP (RB significantly)) (VP (VBN enhanced) (PP (IN in) (NP (NP (DT the) (NNS tissues)) (PP (IN of) (NP (NP (ADJP (ADJP (JJ normal)) (CC and) (ADJP (NN _PROT1_) (JJ fed))) (NNS rats)) (VP (VBN administered) (NP (NP (ADJP (CD 1) (NN mg)) (NN _PROT2_)) (PP (IN from) (NP (NN brinjal/100) (NN g) (NN BW/day)))))))))))))))))
-1 #(S1 (S (NP (NP (NNS METHODS)) (: :) (S (NP (PRP We)) (VP (VBP have) (ADVP (RB therefore)) (VP (VBN studied) (NP (NP (NP (NP (JJ possible) (NNS associations)) (PP (IN of) (NP (DT the) (NN Gln27Glu)))) (CC and) (NP (NP (DT the) (NN Gly16Arg) (NNS polymorphisms)) (PP (IN in) (NP (NP (DT the) (NN beta2AR)) (PP (IN with) (NP (NN BMI))))))) (, ,) (NP (NP (NN plasma) (NN _PROT1_)) (CC and) (NP (NN _PROT2_) (NN mRNA) (NN expression)))) (PP (IN in) (NP (NP (DT the) (JJ intraperitoneal) (NN adipose) (NN tissue)) (PP (IN in) (NP (NP (DT a) (NN population)) (PP (IN of) (NP (NN Caucasian) (NNS women)))))))))))))
-1 #(S1 (S (ADVP (RB Furthermore)) (, ,) (NP (DT no) (NN association)) (VP (VBD was) (VP (VBN found) (PP (IN between) (NP (NP (DT the) (NP (NP (NN Gln27Glu)) (CC or) (NP (DT the) (NN Gly16Arg))) (NNS polymorphisms)) (CC and) (NP (NP (NN plasma) (NN _PROT1_)) (CC or) (NP (NN adipose) (NN tissue)) (NP (NN _PROT2_) (NN gene) (NN expression))))) (PP (IN in) (NP (DT either) (NN group)))))))
-1 #(S1 (S (NP (NP (ADJP (FW In) (FW vivo)) (NNS effects)) (PP (IN of) (NP (NN CGP-12177))) (PP (IN on) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NP (NN _PROT1_)) (CC and) (NP (NN _PROT2_) (NN _PROT2_) (NNS genes)))) (PP (IN in) (NP (NN mouse) (ADJP (ADJP (JJ brown)) (CC and) (ADJP (JJ white))) (NN adipose) (NNS tissues))))))))
-1 #(S1 (S (NP (NP (NN OBJECTIVE)) (: :) (S (VP (TO To) (VP (VB assess) (NP (NP (DT the) (NN effect)) (PP (PP (IN of) (NP (NP (JJ chronic) (NN treatment)) (PP (IN with) (NP (NP (CD CGP-12177)) (NP (DT a) (JJ beta3-adrenergic) (NN receptor) (-LRB- -LRB-) (NN AR) (-RRB- -RRB-) (NN agonist)))) (PP (IN with) (NP (JJ beta2/beta1-AR) (NN antagonist) (NN action))))) (, ,) (PP (IN on) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (DT the) (NN _PROT1_) (NN gene))))) (CC and) (PP (IN of) (NP (NP (NNS genes)) (VP (VBG coding) (PP (IN for) (NP (NP (NN _PROT2_) (NNS _PROT2_)) (PRN (-LRB- -LRB-) (NP (NP (NN ucp1)) (, ,) (NP (NN ucp2)) (CC and) (NP (NN ucp3))) (-RRB- -RRB-)))))))) (PP (IN in) (NP (ADJP (ADJP (JJ brown)) (CC and) (ADJP (JJ white))) (NN adipose) (NNS tissues))))))))))
-1 #(S1 (S (NP (NP (NN CONCLUSION)) (: :) (S (NP (DT The) (NNS results)) (VP (VP (VBP reveal) (SBAR (IN that) (S (NP (NP (JJ simultaneous) (NN stimulation)) (PP (IN of) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NP (JJ certain) (NN _PROT1_) (NNS genes)) (CC and) (NP (DT the) (NN _PROT2_) (NN gene))))))) (VP (MD can) (VP (VB be) (VP (VBN achieved))))))) (, ,) (CC and) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (JJ adrenergic) (NN regulation)) (PP (PP (IN of) (NP (DT the) (NN _PROT_) (NN gene))) (CC and) (PP (IN of) (NP (NP (NNS genes)) (PP (IN of) (NP (NP (DT the) (NN _PROT_) (NN family)) (PP (IN in) (NP (JJ adipose) (NNS tissues))))))))) (VP (VBZ is) (NP (NP (DT the) (NN result)) (PP (IN of) (NP (NP (JJ complex) (NNS interactions)) (PP (IN between) (NP (DT the) (JJ different) (JJ beta-AR) (NNS pathways)))))))))))))))
-1 #(S1 (S (NP (NP (NN CONCLUSION)) (: :) (S (NP (DT The) (NNS results)) (VP (VP (VBP reveal) (SBAR (IN that) (S (NP (NP (JJ simultaneous) (NN stimulation)) (PP (IN of) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NP (JJ certain) (NN _PROT1_) (NNS genes)) (CC and) (NP (DT the) (NN _PROT_) (NN gene))))))) (VP (MD can) (VP (VB be) (VP (VBN achieved))))))) (, ,) (CC and) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (JJ adrenergic) (NN regulation)) (PP (PP (IN of) (NP (DT the) (NN _PROT2_) (NN gene))) (CC and) (PP (IN of) (NP (NP (NNS genes)) (PP (IN of) (NP (NP (DT the) (NN _PROT_) (NN family)) (PP (IN in) (NP (JJ adipose) (NNS tissues))))))))) (VP (VBZ is) (NP (NP (DT the) (NN result)) (PP (IN of) (NP (NP (JJ complex) (NNS interactions)) (PP (IN between) (NP (DT the) (JJ different) (JJ beta-AR) (NNS pathways)))))))))))))))
-1 #(S1 (S (NP (NP (NN CONCLUSION)) (: :) (S (NP (DT The) (NNS results)) (VP (VP (VBP reveal) (SBAR (IN that) (S (NP (NP (JJ simultaneous) (NN stimulation)) (PP (IN of) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NP (JJ certain) (NN _PROT1_) (NNS genes)) (CC and) (NP (DT the) (NN _PROT_) (NN gene))))))) (VP (MD can) (VP (VB be) (VP (VBN achieved))))))) (, ,) (CC and) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (JJ adrenergic) (NN regulation)) (PP (PP (IN of) (NP (DT the) (NN _PROT_) (NN gene))) (CC and) (PP (IN of) (NP (NP (NNS genes)) (PP (IN of) (NP (NP (DT the) (NN _PROT2_) (NN family)) (PP (IN in) (NP (JJ adipose) (NNS tissues))))))))) (VP (VBZ is) (NP (NP (DT the) (NN result)) (PP (IN of) (NP (NP (JJ complex) (NNS interactions)) (PP (IN between) (NP (DT the) (JJ different) (JJ beta-AR) (NNS pathways)))))))))))))))
-1 #(S1 (S (NP (NP (NN CONCLUSION)) (: :) (S (NP (DT The) (NNS results)) (VP (VP (VBP reveal) (SBAR (IN that) (S (NP (NP (JJ simultaneous) (NN stimulation)) (PP (IN of) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NP (JJ certain) (NN _PROT_) (NNS genes)) (CC and) (NP (DT the) (NN _PROT1_) (NN gene))))))) (VP (MD can) (VP (VB be) (VP (VBN achieved))))))) (, ,) (CC and) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (JJ adrenergic) (NN regulation)) (PP (PP (IN of) (NP (DT the) (NN _PROT2_) (NN gene))) (CC and) (PP (IN of) (NP (NP (NNS genes)) (PP (IN of) (NP (NP (DT the) (NN _PROT_) (NN family)) (PP (IN in) (NP (JJ adipose) (NNS tissues))))))))) (VP (VBZ is) (NP (NP (DT the) (NN result)) (PP (IN of) (NP (NP (JJ complex) (NNS interactions)) (PP (IN between) (NP (DT the) (JJ different) (JJ beta-AR) (NNS pathways)))))))))))))))
-1 #(S1 (S (NP (NP (NN CONCLUSION)) (: :) (S (NP (DT The) (NNS results)) (VP (VP (VBP reveal) (SBAR (IN that) (S (NP (NP (JJ simultaneous) (NN stimulation)) (PP (IN of) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NP (JJ certain) (NN _PROT_) (NNS genes)) (CC and) (NP (DT the) (NN _PROT1_) (NN gene))))))) (VP (MD can) (VP (VB be) (VP (VBN achieved))))))) (, ,) (CC and) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (JJ adrenergic) (NN regulation)) (PP (PP (IN of) (NP (DT the) (NN _PROT_) (NN gene))) (CC and) (PP (IN of) (NP (NP (NNS genes)) (PP (IN of) (NP (NP (DT the) (NN _PROT2_) (NN family)) (PP (IN in) (NP (JJ adipose) (NNS tissues))))))))) (VP (VBZ is) (NP (NP (DT the) (NN result)) (PP (IN of) (NP (NP (JJ complex) (NNS interactions)) (PP (IN between) (NP (DT the) (JJ different) (JJ beta-AR) (NNS pathways)))))))))))))))
-1 #(S1 (S (NP (NP (NN CONCLUSION)) (: :) (S (NP (DT The) (NNS results)) (VP (VP (VBP reveal) (SBAR (IN that) (S (NP (NP (JJ simultaneous) (NN stimulation)) (PP (IN of) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NP (JJ certain) (NN _PROT_) (NNS genes)) (CC and) (NP (DT the) (NN _PROT_) (NN gene))))))) (VP (MD can) (VP (VB be) (VP (VBN achieved))))))) (, ,) (CC and) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (JJ adrenergic) (NN regulation)) (PP (PP (IN of) (NP (DT the) (NN _PROT1_) (NN gene))) (CC and) (PP (IN of) (NP (NP (NNS genes)) (PP (IN of) (NP (NP (DT the) (NN _PROT2_) (NN family)) (PP (IN in) (NP (JJ adipose) (NNS tissues))))))))) (VP (VBZ is) (NP (NP (DT the) (NN result)) (PP (IN of) (NP (NP (JJ complex) (NNS interactions)) (PP (IN between) (NP (DT the) (JJ different) (JJ beta-AR) (NNS pathways)))))))))))))))
-1 #(S1 (S (ADVP (RB However)) (, ,) (NP (CC neither) (NP (NN progesterone)) (CC nor) (NP (NN _PROT1_))) (VP (VBD increased) (NP (NP (NN phosphotyrosine)) (PP (IN on) (NP (NN _PROT2_)))))))
-1 #(S1 (S (NP (NP (NN _PROT1_AND_PROT2_)) (: :) (NP (NP (JJ opposing) (NNS effects)) (PP (IN on) (NP (NP (ADJP (ADJP (JJ appetitive)) (CC and) (ADJP (JJ consummatory))) (NN ingestive) (NN behavior)) (CC and) (NP (JJ sexual) (NN behavior))))))))
-1 #(S1 (S (NP (JJ Many) (NNS studies)) (VP (VBP have) (VP (VBN indicated) (SBAR (IN that) (S (S (NP (NP (NN _PROT1_) (NN _PROT1_)) (PRN (-LRB- -LRB-) (NP (NN NPY)) (-RRB- -RRB-))) (VP (VBZ stimulates))) (CC and) (S (NP (NN _PROT2_)) (VP (VBZ inhibits) (NP (NN food) (NN intake))))))))))
-1 #(S1 (S (S (PP (IN In) (NP (NP (NN line)) (PP (IN with) (NP (DT this))))) (, ,) (NP (NP (JJ intracerebroventricular) (NN injection)) (PP (IN of) (NP (NP (NN _PROT1_)) (PRN (-LRB- -LRB-) (NP (CD 10) (NN microg)) (-RRB- -RRB-))))) (VP (VBD stimulated))) (S (CC and) (NP (NP (NN _PROT2_)) (PRN (-LRB- -LRB-) (NP (CD 10) (NN microg)) (-RRB- -RRB-))) (VP (VBD inhibited) (NP (NP (NN intake)) (PP (IN of) (NP (DT a) (NN sucrose) (NN solution)))) (SBAR (WHADVP (WRB when)) (S (NP (JJ female) (NNS rats)) (VP (VBD were) (VP (VBN required) (S (VP (TO to) (VP (VB obtain) (NP (DT the) (NN solution)) (PP (IN from) (NP (DT a) (JJ bottle))))))))))))))
-1 #(S1 (S (ADVP (RB However)) (, ,) (S (S (NP (NN _PROT1_)) (VP (VBD inhibited))) (CC and) (S (NP (NN _PROT2_)) (VP (VBD stimulated) (NP (NN intake)) (SBAR (IN if) (S (NP (DT the) (NN solution)) (VP (VBD was) (VP (VBN infused) (ADVP (RB intraorally)))))))))))
-1 #(S1 (S (S (ADVP (RB Thus)) (NP (NN _PROT1_)) (VP (VP (VBZ stimulates) (NP (NP (DT the) (NNS responses)) (VP (VBN used) (S (VP (TO to) (VP (VB obtain) (NP (NN food)))))))) (CC but) (VP (VBZ inhibits) (NP (NP (DT those)) (VP (VBN used) (S (VP (TO to) (VP (VB consume) (NP (NN food)))))))))) (, ,) (CC and) (S (NP (NN _PROT2_)) (VP (VBZ has) (NP (DT the) (JJ opposite) (NNS effects))))))
+1 #(S1 (S (NP (PRP We)) (ADVP (RB also)) (VP (VBD determined) (SBAR (IN whether) (S (NP (NP (ADJP (RB well) (JJ known)) (JJ hypothalamic) (NN neuropeptide) (NNS targets)) (, ,) (PP (FW e.g.) (NP (NP (NP (NN _PROT1_) (NN _PROT1_)) (PRN (-LRB- -LRB-) (NP (NN NPY)) (-RRB- -RRB-))) (, ,) (NP (NP (NN proopiomelanocortin)) (PRN (-LRB- -LRB-) (NP (JJ POMC)) (-RRB- -RRB-))) (, ,) (NP (NP (JJ agouti-related) (NN peptide)) (PRN (-LRB- -LRB-) (NP (NN AGRP)) (-RRB- -RRB-))) (CC and) (NP (NP (NN cocaine)) (CC and) (NP (NP (JJ amphetamine-regulated) (NN transcript)) (PRN (-LRB- -LRB-) (NP (NN CART)) (-RRB- -RRB-))))))) (VP (VBD were) (VP (VBN regulated) (PP (IN in) (NP (NP (DT a) (NN pattern)) (ADJP (JJ consistent) (PP (IN with) (NP (PRP$ their) (JJ presumed) (NNS roles)))))) (PP (IN as) (NP (NP (NNS mediators)) (PP (IN of) (NP (NN _PROT2_) (NN action))))))))))))
+1 #(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NN _PROT1_)) (VP (VP (VBD decreased) (NP (NP (NN body) (NN weight)) (CC and) (NP (NN adiposity)))) (, ,) (VP (VBD increased) (NP (NN CART))) (CC and) (VP (VBD suppressed) (NP (NP (NP (NP (NN _PROT2_)) (CC and) (NP (NN AGRP))) (NN mRNA) (NN expression)) (PP (IN in) (NP (JJ adult) (NNS mice))))))))
